Clinical Trial Update: Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

This clinical trial update covers a Phase 2 study of erlotinib in combination with chemotherapy for triple-negative breast cancer. The current status of the tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN